Ignite Creation Date:
2025-12-24 @ 7:39 PM
Ignite Modification Date:
2025-12-25 @ 5:19 PM
Study NCT ID:
NCT01693003
Status:
COMPLETED
Last Update Posted:
2014-01-08
First Post:
2012-09-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D029424', 'term': 'Pulmonary Disease, Chronic Obstructive'}], 'ancestors': [{'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C510790', 'term': 'indacaterol'}, {'id': 'D000069447', 'term': 'Tiotropium Bromide'}], 'ancestors': [{'id': 'D012602', 'term': 'Scopolamine Derivatives'}, {'id': 'D014326', 'term': 'Tropanes'}, {'id': 'D053961', 'term': 'Azabicyclo Compounds'}, {'id': 'D001372', 'term': 'Aza Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D019086', 'term': 'Bridged Bicyclo Compounds, Heterocyclic'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-01', 'completionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-01-06', 'studyFirstSubmitDate': '2012-09-19', 'studyFirstSubmitQcDate': '2012-09-25', 'lastUpdatePostDateStruct': {'date': '2014-01-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-09-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Adverse events', 'timeFrame': 'Participants will register adverse events in clinical research diaries or communicate to investigator during 3-week treatment period', 'description': 'Adverse events, including serious adverse events, will be collected and reported in the CRF (Clinical Research File) of the study.\n\nAdverse event is any sign, symptom or undesired medical condition that occurs after the beginning of the study even if said event is not considered related to the drug (or therapy) of study. Information on adverse events either reported voluntarily by the patient, identified through questioning by the investigator, or detected by physical examination, laboratory testing or otherwise, will be collected and recorded.'}], 'primaryOutcomes': [{'measure': 'Exercise tolerance', 'timeFrame': '3 weeks', 'description': 'Time between beginning of high intensity constant load (75-85% of the peak achieved in a previous cycloergometer incremental test) cardiopulmonary exercise test and point at which patient cannot tolerate the effort any longer.'}], 'secondaryOutcomes': [{'measure': 'Effort-related dyspnea during daily activities', 'timeFrame': '3 weeks'}, {'measure': 'Airway diameter and volume, and extension of pulmonary emphysema by multidetector helical chest computed tomography', 'timeFrame': '3 weeks'}, {'measure': 'Oxidative stress before and after exercise tests', 'timeFrame': '3 weeks'}, {'measure': 'Exercise dyspnea', 'timeFrame': '3 weeks', 'description': 'Dyspnea evaluated by Borg scale each 2 minutes during high intensity constant load cardiopulmonary exercise test until exhaustion (peak exercise)'}, {'measure': 'Dynamic pulmonary hyperinflation', 'timeFrame': '3 weeks', 'description': 'Inspiratory capacity measured each 2 minutes during high intensity constant load cardiopulmonary exercise test until exhaustion (peak exercise).'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['COPD'], 'conditions': ['Chronic Obstructive Pulmonary Disease']}, 'referencesModule': {'references': [{'pmid': '27812637', 'type': 'DERIVED', 'citation': 'Berton DC, Santos AH, Bohn I Jr, Lima RQ, Breda V, Teixeira PJ. Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study. J Bras Pneumol. 2016 Sep-Oct;42(5):367-373. doi: 10.1590/S1806-37562015000000334.'}]}, 'descriptionModule': {'briefSummary': "Exercise intolerance is a major complain of patients with chronic obstructive pulmonary disease (COPD). Dynamic hyperinflation has been recognized as an important limiting factor responsible for the appearance of intolerable dyspnea during exercise. Regular treatment with long-acting bronchodilators promotes a more sustained reduction of hyperinflation and consequent symptom relief and increase in the patient's ability to overcome physical demands of daily life. Tiotropium bromide (TIO) is a new generation, long-acting anticholinergic bronchodilator that significantly improves lung function, reduces symptoms and improves exercise tolerance in patients with advanced COPD. Indacaterol is a new ultra-long duration (\\>24 h) β2-agonist, which promotes sustained dilation of the bronchi with a once-daily administration. Compared to tiotropium, indacaterol provides evidence that is as effective as tiotropium for bronchodilation, as well as other clinical outcomes such as dyspnea and state of health. However, comparative effects of indacaterol versus tiotropium with regard to outcomes in tolerance, dyspnea and dynamic lung hyperinflation during exercise is scarce. We hypothesized that indacaterol and TIO are not different in terms of exercise tolerance and its determinants (dynamic hyperinflation and dyspnea)."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Men and women (neither pregnant nor nursing women) ≥40 years of age, with a history of smoking (\\>20 years/pack) and COPD diagnosis according to GOLD criteria.\n* Post-bronchodilator FEV1 \\>50% and \\<80%, and FEV1/FVC ≤70% of predicted value.\n\nExclusion Criteria:\n\n* Hospital admission due to COPD exacerbation or lung infection in the 6 weeks prior to screening, diagnosis of current or previous bronchial asthma, history of allergic rhinitis or other atopic diseases, or peripheral eosinophilia \\>400/mm3.\n* Inability to discontinue the usual bronchodilator therapy prior to initial screening tests, need for continuous oxygen therapy, or arterial oxygen saturation \\<85% at rest, or history of adverse reactions to sympathomimetic amines or use of inhaled medication.\n* Anemia, hypo- or hyperthyroidism, hyperadrenergic conditions, uncontrolled insulin-dependent diabetes mellitus, malignancy, or any disease or condition that limits exercise capacity other than COPD.\n* History of drug or alcohol abuse, poor adherence to drug treatment, or treatment with any investigational drug in the month before screening.\n* Patients with ventricular arrhythmia.\n* Patients with \\<80% oxyhemoglobin saturation during exercise testing'}, 'identificationModule': {'nctId': 'NCT01693003', 'briefTitle': 'Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD', 'organization': {'class': 'OTHER', 'fullName': 'Irmandade Santa Casa de Misericórdia de Porto Alegre'}, 'officialTitle': 'Randomized, Open-label, Crossover Clinical Trial to Assess the Effects of Indacaterol 150 µg d.o. Compared to Tiotropium Bromide 5 µg d.o. on Dyspnea, Dynamic Pulmonary Hyperinflation and Exercise Tolerance in Patients With Moderate COPD', 'orgStudyIdInfo': {'id': 'ISCMPALABAtrial'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Indacaterol first', 'description': 'Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a "wash-out" phase of at least 5 to 14 days between each treatment period', 'interventionNames': ['Drug: Indacaterol', 'Drug: Tiotropium']}, {'type': 'EXPERIMENTAL', 'label': 'Tiotropium first', 'description': 'Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a "wash-out" phase of at least 5 to 14 days between each treatment period', 'interventionNames': ['Drug: Indacaterol', 'Drug: Tiotropium']}], 'interventions': [{'name': 'Indacaterol', 'type': 'DRUG', 'otherNames': ['Onbrez Breezhaler®'], 'description': '150 µg d.o. during the first 3 weeks', 'armGroupLabels': ['Indacaterol first', 'Tiotropium first']}, {'name': 'Tiotropium', 'type': 'DRUG', 'otherNames': ['Spiriva Respimat®'], 'description': '150 µg d.o. during 3 weeks', 'armGroupLabels': ['Indacaterol first', 'Tiotropium first']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90002-090', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Pavilhão Pereira Filho', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Pavilhão Pereira Filho', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}], 'overallOfficials': [{'name': 'Paulo Z Teixeira, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Santa Casa de Porto Alegre'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Irmandade Santa Casa de Misericórdia de Porto Alegre', 'class': 'OTHER'}, 'collaborators': [{'name': 'Novartis', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Clinical professor and chair of the study', 'investigatorFullName': 'Paulo J Z Teixeira', 'investigatorAffiliation': 'Irmandade Santa Casa de Misericórdia de Porto Alegre'}}}}